Shanghai Century Buys China's Largest IV Solutions Producer (China)
This article was originally published in PharmAsia News
Executive SummaryPublicly-listed holding company Shanghai Century Acquisition is purchasing China's largest producer of intravenous solution products, Sichuan Kelun Pharmaceutical (SKP). The holding company will provide SKP's 18 owners with a total of 20 million of its shares as payment in the deal. SKP earned $14.5 million in profits in 2006 based on $176.7 million in revenue. (Click here for more
You may also be interested in...
CEO Vas Narasimhan is confident the Swiss major's gene therapy for spinal muscular atrophy will outperform present and future rivals – Biogen's Spinraza and Roche's risdiplam, respectively – as "we have a better profile simply because we are a one-time therapy."
A new coronavirus test template developed by the US Centers for Disease Control and Prevention is being refined by the agency so it can be shared with domestic and international partners to help identify more cases of the virus. In the meantime, state labs can use the posted assay for coronavirus on the CDC’s website for testing of residents within their jurisdiction and send results to the CDC.
The pharmaceutical industry will be watching carefully as the EU Court of Justice deliberates on whether to deny or widen the granting of supplementary protection certificates on new therapeutic indications of authorized medicines.